Medial EarlySign

Medial EarlySign is a pioneering company that develops AI-based clinical predictive analytics solutions to enable early detection and prevention of high-burden diseases. Their flagship product, LungFlag, is a computational clinical software model designed to help healthcare providers identify individuals at elevated risk for lung cancer who warrant further evaluation. It analyzes routine data from electronic health records (EHRs) to flag high-risk patients for respiratory or pulmonary illnesses.

EarlySign's solutions leverage machine learning algorithms to derive actionable and personalized clinical insights from massive amounts of health data. Their AI models aim to identify and prioritize patients when interventions have a higher chance of halting or preventing disease onset and complications. In November 2023, EarlySign partnered with Geisinger Health System to launch LungFlag and enable earlier interventions for lung cancer within Geisinger's value-based care model.

In addition to LungFlag, EarlySign offers other validated clinical solutions impacting early diagnosis, such as models targeting influenza complications, diabetes, and lower gastrointestinal disorders like colorectal cancer. Their ColonFlag algorithm, marketed as LGI-Flag in the US, was included in Roche's navify Algorithm Suite in May 2023 to support enhanced clinical decision-making.

EarlySign has conducted numerous studies and published peer-reviewed research in collaboration with internationally recognized health organizations and hospitals. The company was a winner of the CMS AI Health Outcomes Challenge and was founded in 2013, headquartered in Tel Aviv, Israel.